What factors predict pathological upstaging in clinical stage T1 renal cell carcinoma?
Pathological upstaging means that after surgery, the cancer is found to be more advanced than imaging suggested before surgery. For clinical stage T1 renal cell carcinoma (RCC), this happens in about 5-20% of cases. Knowing which factors increase the risk of upstaging can help doctors and patients plan treatment more accurately.
What the research says
A large systematic review of 17 studies (nearly 25,000 patients) found that the overall rate of pathological upstaging to pT3a was 7.46% 5. Independent risk factors included male gender (odds ratio [OR] 1.07), older age (OR 1.03 per year), higher body mass index (OR 1.02), clinical stage T1b (tumor size 4-7 cm; OR 5.87), presence of clinical symptoms (OR 1.99), a RENAL nephrometry score of 7-9 (OR 2.48), necrosis on imaging (OR 2.35), irregular tumor margins (OR 2.87), and hilus involvement (OR 2.13) 5.
Other studies confirm similar findings. A 2023 study of 289 patients reported that higher platelet-lymphocyte ratio (PLR), higher AST/ALT ratio (De Ritis ratio), higher Fuhrman grade, and clear cell subtype were also significant predictors 9. A 2024 study of 159 patients found that larger tumor size, higher RENAL score, higher systemic immune-inflammation index (SII), and greater peritumoral fatty tissue thickness were associated with upstaging 10. Another study of 1,376 patients identified age, clinical symptoms, tumor size, Fuhrman grade, tumor necrosis, and irregular tumor edges as predictors, and built nomograms to estimate individual risk 11.
These factors can be grouped into patient characteristics (age, sex, BMI), tumor features on imaging (size, margins, necrosis, RENAL score), and lab values (PLR, SII, De Ritis ratio). Upstaging is important because it is linked to worse outcomes: one study found that 5-year recurrence-free survival was 73.3% in upstaged patients versus 91.1% in those who were not upstaged 11.
What to ask your doctor
- Based on my tumor size, RENAL score, and imaging features, what is my estimated risk of pathological upstaging?
- Should any additional blood tests (like PLR, SII, or De Ritis ratio) be done before surgery to refine the risk assessment?
- If upstaging is found after surgery, how would that change my follow-up plan or need for additional treatment?
- Are there any nomograms or prediction tools you can use to estimate my individual risk of upstaging?
This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.